FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2759259140> ?p ?o ?g. }

• W2759259140 endingPage "E397" @default.
• W2759259140 startingPage "E396" @default.
• W2759259140 abstract "The funding landscape for oncology clinical trials is changing with increasing industry support and decreasing NIH funding. This study aims to characterize sources of funding for interventional clinical trials utilizing radiation therapy (RT), and the status of radiation oncologist (RO) principal investigator (PI) leadership of such clinical trials. We queried clinicaltrials.gov for all open, interventional, phase I-III trials that included RT. Search terms included “radiation therapy” and specific disease-sites within oncologic subspecialties (breast, CNS, genitourinary, gastrointestinal, gynecologic, head and neck, hematologic, sarcoma, thoracic.) Trials were excluded if they did not include RT or were restricted to pediatric patients. Chi-squared testing and logistic regression were used to identify significant associations between clinical trial characteristics and RO PI leadership, and receipt of specific funding types (NIH, industry, or other.) 1,201 trials met the inclusion criteria, of which 41% are US-based trials, 56% international, and 3% both US and international. Radiation oncologists lead 58% of trials, medical oncologists (MO) 22%, surgeons 12%, and other specialties 8%. Types of trials were categorized as 43% RT + drug, 26% RT + drug + surgery, 18% RT alone, and 13% RT + surgery. Among all trials, 49% use chemotherapy, 11% immunotherapy, 9% small molecule inhibitors, 6% biologic therapy, 4% hormonal therapy, and 11% other drug therapies. RO PIs are significantly less likely than other specialties to be the PI on trials involving drug therapy (odds ratio [OR] = 0.23, 95% confidence interval [CI], 0.17-0.31, p<0.001), or surgery (OR=0.71; 95% CI, 0.51-0.99). Funding patterns also vary significantly based on trial-type and PI specialty as RO are significantly more likely to rely on non-NIH/non-industry funding (OR=2.34; 95% CI, 1.23-4.45). Industry funding is more common for trials led by medical oncologists compared with RO (58% vs. 15%, P<0.001), for Phase I (OR=3.11; 95% CI, 1.49-6.47) and II trials (OR=2.30; 95% CI, 1.18-4.47), and trials incorporating immunotherapy (OR=10.64; 95% CI, 6.30-17.99), small molecule inhibitors (OR=6.13; 95% CI, 3.43-10.93) or biologics (OR=3.83; 95% CI, 1.91-7.66). NIH-funding is more common for phase III trials (OR=2.38; 95% CI, 1.12-5.03), and there was no significant association with PI-type. Radiation oncologists lead 58% of all trials utilizing RT as an intervention, but only 49% of trials combining RT with drug therapy and are less likely than other specialties to be the PI of trials combining systemic therapy and/or surgery with RT. Furthermore, industry-supported trials are less likely to have RO leadership. These data suggest a need for RO to advocate for greater leadership in multi-modality trials, NIH-support, and collaboration with industry." @default.
• W2759259140 created "2017-10-06" @default.
• W2759259140 creator A5015096941 @default.
• W2759259140 creator A5024024612 @default.
• W2759259140 creator A5024038350 @default.
• W2759259140 creator A5055709149 @default.
• W2759259140 creator A5073653003 @default.
• W2759259140 creator A5077566206 @default.
• W2759259140 date "2017-10-01" @default.
• W2759259140 modified "2023-09-30" @default.
• W2759259140 title "The Current State of Funding and Radiation Oncologist Leadership of Clinical Trials Utilizing Radiation Therapy" @default.
• W2759259140 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1550" @default.
• W2759259140 hasPublicationYear "2017" @default.
• W2759259140 type Work @default.
• W2759259140 sameAs 2759259140 @default.
• W2759259140 citedByCount "1" @default.
• W2759259140 countsByYear W27592591402019 @default.
• W2759259140 crossrefType "journal-article" @default.
• W2759259140 hasAuthorship W2759259140A5015096941 @default.
• W2759259140 hasAuthorship W2759259140A5024024612 @default.
• W2759259140 hasAuthorship W2759259140A5024038350 @default.
• W2759259140 hasAuthorship W2759259140A5055709149 @default.
• W2759259140 hasAuthorship W2759259140A5073653003 @default.
• W2759259140 hasAuthorship W2759259140A5077566206 @default.
• W2759259140 hasBestOaLocation W27592591401 @default.
• W2759259140 hasConcept C126322002 @default.
• W2759259140 hasConcept C143998085 @default.
• W2759259140 hasConcept C509974204 @default.
• W2759259140 hasConcept C535046627 @default.
• W2759259140 hasConcept C71924100 @default.
• W2759259140 hasConceptScore W2759259140C126322002 @default.
• W2759259140 hasConceptScore W2759259140C143998085 @default.
• W2759259140 hasConceptScore W2759259140C509974204 @default.
• W2759259140 hasConceptScore W2759259140C535046627 @default.
• W2759259140 hasConceptScore W2759259140C71924100 @default.
• W2759259140 hasIssue "2" @default.
• W2759259140 hasLocation W27592591401 @default.
• W2759259140 hasOpenAccess W2759259140 @default.
• W2759259140 hasPrimaryLocation W27592591401 @default.
• W2759259140 hasRelatedWork W2015309066 @default.
• W2759259140 hasRelatedWork W2021771973 @default.
• W2759259140 hasRelatedWork W2022944059 @default.
• W2759259140 hasRelatedWork W2048191766 @default.
• W2759259140 hasRelatedWork W2168923614 @default.
• W2759259140 hasRelatedWork W2384708512 @default.
• W2759259140 hasRelatedWork W2428341374 @default.
• W2759259140 hasRelatedWork W2804642607 @default.
• W2759259140 hasRelatedWork W2897496508 @default.
• W2759259140 hasRelatedWork W4253632170 @default.
• W2759259140 hasVolume "99" @default.
• W2759259140 isParatext "false" @default.
• W2759259140 isRetracted "false" @default.
• W2759259140 magId "2759259140" @default.
• W2759259140 workType "article" @default.